(NASDAQ:HGEN) shares are trading higher on positive financial results. Biotechnology is still a hot sector.

(NASDAQ:HGEN) shares are trading higher on positive financial results. Biotechnology is still a hot sector.

Humanigen Reports First Quarter 2022 Financial Results

SHORT HILLS, N.J.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab (LENZ), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

Read the entire artilcle: https://www.businesswire.com/news/home/20220505005996/en/Humanigen-Reports-First-Quarter-2022-Financial-Results

JOIN OUR NEWSLETTER

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist